KR920016086A - 흡입용의 반응억제성 천식치료 활성을 갖는 비스테로이드성 소염제 - Google Patents

흡입용의 반응억제성 천식치료 활성을 갖는 비스테로이드성 소염제 Download PDF

Info

Publication number
KR920016086A
KR920016086A KR1019920001737A KR920001737A KR920016086A KR 920016086 A KR920016086 A KR 920016086A KR 1019920001737 A KR1019920001737 A KR 1019920001737A KR 920001737 A KR920001737 A KR 920001737A KR 920016086 A KR920016086 A KR 920016086A
Authority
KR
South Korea
Prior art keywords
nonsteroidal anti
inhalation
inflammatory agent
inflammatory drugs
inhibitory
Prior art date
Application number
KR1019920001737A
Other languages
English (en)
Inventor
비안코 세바스티아노
Original Assignee
엥겔하르트, 라피체
훼스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엥겔하르트, 라피체, 훼스트 아크티엔게젤샤프트 filed Critical 엥겔하르트, 라피체
Publication of KR920016086A publication Critical patent/KR920016086A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

[발명의 명칭]
흡입용의 반응억제성 천식치료 활성을 갖는 비스테로이드성 소염제
[도면의 간단한 설명]
제1도는 L-ASA(100mg/m1)를 흡입 치료하고 30초후 및 24시간후에 측정한 UNW에 대한 기관지 반응성에 대한 L-ASA흡입 치료 효과를 도시한 것이다. 데이타는 UNW PD20의 M±SE로서 표시된다, 제2도는 UMW에 대한 기관지 반응성에 대한 인도메타신(5mg/m1)흡입 치료의 효과를 도시한 것이다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 천식 치료를 위해 흡입되는 약제 제조용으로서의 비스테로이드성 소염제의 용도.
  2. 제1항에 있어서, 비스테로이드성 소염제가 아세틸 살리실산인 용도.
  3. 제1항에 있어서, 비스테로이드성 소염제가 인도메타신의 용도.
  4. 제1항에 있어서, 비스테로이드성 소염제가 케토프로펜인 용도.
  5. 제1항에 있어서, 비스테로이드성 소염제가 테녹시캄인 용도.
  6. 천식 억제시 흡입법으로 사용되는 비스테로이드성 소염제.
  7. 제6항에 있어서, 아세틸살리실산인 비스테로이드성 소염제.
  8. 제6항에 있어서, 인도메타신인 비스테로이드성 소염제.
  9. 제6항에 있어서, 케토프로펜인 비스테로이드성 소염제.
  10. 제6항에 있어서, 테녹시캄인 비스테로이드성 소염제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920001737A 1991-02-09 1992-02-07 흡입용의 반응억제성 천식치료 활성을 갖는 비스테로이드성 소염제 KR920016086A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91101818.2 1991-02-09
EP91101818 1991-02-09

Publications (1)

Publication Number Publication Date
KR920016086A true KR920016086A (ko) 1992-09-24

Family

ID=8206393

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920001737A KR920016086A (ko) 1991-02-09 1992-02-07 흡입용의 반응억제성 천식치료 활성을 갖는 비스테로이드성 소염제

Country Status (16)

Country Link
US (1) US6051566A (ko)
JP (1) JPH0648958A (ko)
KR (1) KR920016086A (ko)
AT (1) ATE179605T1 (ko)
AU (1) AU662509B2 (ko)
BR (1) BR9200429A (ko)
CA (1) CA2060937A1 (ko)
CZ (1) CZ281970B6 (ko)
DE (1) DE69229070T2 (ko)
HU (1) HUT60917A (ko)
IE (1) IE920427A1 (ko)
IL (1) IL100896A (ko)
MX (1) MX9200571A (ko)
NO (1) NO179893C (ko)
NZ (1) NZ241542A (ko)
ZA (1) ZA92890B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110020169A (ko) * 2009-08-21 2011-03-02 포항공과대학교 산학협력단 Ｉｌ－１７ 매개 염증질환의 치료를 위한 조합 제제 및 이를 이용한 치료 방법

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1280520B2 (en) 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
DE60230609D1 (de) * 2001-05-24 2009-02-12 Alexza Pharmaceuticals Inc Verabreichung von nichtsteroidalen entzündungshemmenden wirkstoffen durch inhalation
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
WO2002094218A2 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
EP1450787A4 (en) 2001-11-15 2006-01-25 Galileo Pharmaceuticals Inc FORMULATIONS AND METHODS FOR THE TREATMENT OR AMELIORATION OF INFLAMMATORY CONDITIONS
AU2002363947A1 (en) * 2001-11-21 2003-07-24 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
EP1503744A1 (en) 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US20060193788A1 (en) * 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
JP2006514633A (ja) * 2002-11-26 2006-05-11 アレックザ ファーマシューティカルズ， インコーポレイテッド 吸入によって送達される抗精神病薬を用いた頭痛の治療
CA2507159A1 (en) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
CA2526475A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
ITMI20050417A1 (it) * 2005-03-15 2006-09-16 Medestea Res & Production S R L Uso di farmaci anti-infiammatori non steroidei per via inalatoria nella terapia della bronchite acuta e cronica
AR059357A1 (es) * 2006-02-09 2008-03-26 Schering Corp Formulaciones farmaceuticas
JP5094197B2 (ja) * 2006-04-27 2012-12-12 第一三共ヘルスケア株式会社 杯細胞過形成を抑制するための抗ヒスタミン剤含有医薬組成物
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
DE102008004386A1 (de) * 2008-01-14 2009-07-23 Activaero Gmbh Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
EP2280995A2 (en) * 2008-04-29 2011-02-09 Wyeth LLC Methods for treating inflammation
US20130281405A1 (en) * 2012-04-02 2013-10-24 Lenard M. Lichtenberger Use of pc-nsaids to treat and/or prevent pulmonary inflammation
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3607941A1 (en) * 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
TWI586383B (zh) * 2014-04-18 2017-06-11 林信湧 一種用於治療關節炎之吸入式醫藥組成物及其備製方法
EP3191091B1 (en) 2014-09-12 2020-08-26 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
US11723864B2 (en) * 2015-05-29 2023-08-15 The Texas A&M University System Antimicrobial and anti-inflammatory compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244899A (en) * 1985-02-04 1993-09-14 G. D. Searle And Co. Azabicycloalkyl and azatricycloalkyl amides used to treat inflammation, allergy, asthma and skin disorders
US4885287A (en) * 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110020169A (ko) * 2009-08-21 2011-03-02 포항공과대학교 산학협력단 Ｉｌ－１７ 매개 염증질환의 치료를 위한 조합 제제 및 이를 이용한 치료 방법

Also Published As

Publication number Publication date
HUT60917A (en) 1992-11-30
AU662509B2 (en) 1995-09-07
NO920504D0 (no) 1992-02-07
CA2060937A1 (en) 1992-08-10
CS35292A3 (en) 1992-08-12
IE920427A1 (en) 1992-08-12
ZA92890B (en) 1992-12-30
HU9200389D0 (en) 1992-04-28
MX9200571A (es) 1992-12-01
NZ241542A (en) 1996-05-28
DE69229070T2 (de) 1999-11-18
IL100896A0 (en) 1992-11-15
DE69229070D1 (de) 1999-06-10
NO920504L (no) 1992-08-10
CZ281970B6 (cs) 1997-04-16
IL100896A (en) 1998-02-22
NO179893B (no) 1996-09-30
BR9200429A (pt) 1992-10-13
AU1077292A (en) 1992-08-13
ATE179605T1 (de) 1999-05-15
JPH0648958A (ja) 1994-02-22
US6051566A (en) 2000-04-18
NO179893C (no) 1997-01-08

Similar Documents

Publication Publication Date Title
KR920016086A (ko) 흡입용의 반응억제성 천식치료 활성을 갖는 비스테로이드성 소염제
Davis et al. Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
Wallace et al. Novel nonsterodial anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat
ES2316571T3 (es) Administracion de alprazolam, estazolam, midazolam o triazolam a traves de una via inhalatoria.
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
US20040184996A1 (en) Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
BR9908587A (pt) Inalador de pó
EP1787639A3 (en) Stable pharmaceutical solution formulations for pressurised metered dose inhalers
SI9200403B (en) New combination of a bronchodilator and a steroidal antiinflammatory drug for treatment of respiratory disorders as well as its use and preparation thereof
NO305537B1 (no) Farmas°ytisk preparat inneholdene et definert lipidsystem, og anvendelse av lipidsystemet
BRPI0518266A8 (pt) Medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
BR9915095A (pt) Composição farmacêutica ministrável em aerosol
BR0303348A (pt) Formulações de aerossol para administração pulmonar de medicamentos com o intuito de produzir efeito sistêmico
EP1177793A8 (fr) Aérosol médicamenteux inhalable dans le traitement ou la prévention de la douleur
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
Lynch et al. Etodolac: a preliminary review of its pharmacodynamic activity and therapeutic use
WO2002069968A8 (en) New use
EP1249242B1 (en) Natural-Phytotherapic composition based on hydroglyceric extracts for aerosol therapy
Di Benedetto et al. Inhalation therapy in asthma.
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물
GB1235529A (en) Composition for mucolysis
ATE326220T1 (de) Verabreichungsverfahren von s-adenosylmethionin in form eines mikrofeinen pulvers durch inhalieren
Yealy et al. Informed consent in prehospital research
TH58547A3 (th) การใช้องค์ประกอบซึ่งประกอบรวมด้วยฟอร์โมเทอรอล และบูดิโซไนด์สำหรับการป้องกันและรักษาภาวะหอบหืดรุนแรง
EP0009046A1 (en) Composition containing salicylsalicyclic acid and acetaminophen

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application